← All trials
NCT06500507
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2024
- Primary completion
- Mar 31, 2026
- Completion date
- Jan 31, 2027
- First posted
- Jul 15, 2024
- Last posted
- Jul 15, 2024
- Enrollment
- 90
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Qilu Pharmaceutical Co., Ltd.Lead sponsor
- Chinese Academy of Medical SciencesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.